Gholizadeh, E., et al. (2024). Exploring Mechanisms of Action in Combinatorial Therapies through Solubility Alterations: Advancing AML Treatment. bioRxiv, 2024.11.08.618644. https://doi.org/10.1101/2024.11.08.618644
Gholizadeh, E., et al. (2024). Targeting AML Resistance with LY3009120-Sapanisertib and Ruxolitinib-Ulixertinib Combinations Demonstrate Superior Efficacy in FLT3, TP53, and MUC4 mutations. bioRxiv, 2024.12.31.630711. https://doi.org/10.1101/2024.12.31.630711
Zangene, E., et al. (2023). DORSSAA: Drug-target interactOmics Resource based on Stability/Solubility Alteration Assay.bioRxiv, 2023.12.29.573639. https://doi.org/10.1101/2023.12.29.573639
Jafari, M., et al. (2022). NIMAA: an R/CRAN package to accomplish NomInal data Mining AnAlysis. bioRxiv, 2022.01.13.475835. https://doi.org/10.1101/2022.01.13.475835.